<DOC>
	<DOCNO>NCT01896180</DOCNO>
	<brief_summary>This pilot , proof concept study evaluate safety efficacy ALZ-1101 dose daily 28 day compare latanoprost 0.005 % ophthalmic solution patient elevate intraocular pressure adequately control latanoprost .</brief_summary>
	<brief_title>Study Compare Safety Efficacy ALZ-1101 Latanoprost Patients With Intraocular Pressure Inadequately Controlled Latanoprost</brief_title>
	<detailed_description>This exploratory , pilot , proof concept Phase 2 study . The objective include comparison efficacy ALZ-1101 latanoprost 0.005 % ophthalmic solution reduce elevate intraocular pressure ( IOP ) patient primary open angle glaucoma ocular hypertension IOP adequately control latanoprost . 70 Subjects ( 35 per arm ) treat daily ( QD ) even either ALZ-1101 latanoprost 28 day . Efficacy assess 3 separate time ( 8 AM , 10 AM 4 PM ) treatment visit ( Days 0 , 7 , 14 28 ) Goldmann applanation tonometry . Safety assessment include slit lamp examination/anterior chamber cell flare grade , ophthalmoscopy/fundus examination , visual acuity , visual field test colelction adverse event . Subject rating study medication comfort collect visit . Primary efficacy endpoint between-group comparison mean IOP 10 time point visit 5 ( Day 28 ) . Secondary endpoint include between-group comparison mean change baseline IOP time-points , group comparison mean change baseline diurnal IOP post-baseline visit proportion subject IOP ≤ 18 mm Hg time point post-baseline visit .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Primary openangle glaucoma OH treatment latanoprost 0.005 % QD . 3 . At least one eye IOP &gt; 18 mm Hg ≤ 28 mm Hg time point ( 8 AM , 10 AM , 4 PM ) latanoprost monotherapy QD Screening Baseline ( Day 0 ) visit . Measurements take visit 8 AM , 10 AM , 4 PM ( ± 30 minute ) , AM measurements IOP least 2 hour apart . Screening must least one week within 2 week prior Baseline . 4 . On latanoprost 0.005 % QD least 4 week prior randomization . 5 . Shaffer gonioscopic grade ≥ 3 ( least 3 quadrant ) eye . 6 . Stable correct Snellen visual acuity ( VA ) good 20/200 study eye . 7 . Central corneal thickness 480620 μm study eye . 8 . Female subject must 1year postmenopausal , surgically sterilize , woman childbearing potential negative urine pregnancy test Visit 1 . Women childbearing potential must use acceptable form contraception throughout study . Acceptable method include use least one following : intrauterine ( intrauterine device ) , hormonal ( oral , injection , patch , implant , ring ) , barrier spermicide ( condom , diaphragm ) , abstinence . 9 . Provide sign write consent prior participation studyrelated procedure . 1 . A mean deviation &lt; 20 dB visual field ( VF ) assessment . 2 . Presence scotoma within 5°of fixation VF . 3 . Aphakia . 4 . Use antiglaucoma medication addition latanoprost QD within 2 week prior Visit 1 study period . 5 . Use topical ophthalmic steroid nonsteroidal antiinflammatory drug ( NSAID ) within 2 week prior Visit 1 study period . 6 . Use systemic carbonic anhydrase inhibitor within 2 week prior Visit 1 study period . 7 . Ocular surgery ocular laser treatment kind within 3 month prior Visit 1 study period . 8 . Any history glaucoma surgery ( laser nonlaser ) . 9 . History ocular allergy/inflammation and/or severe blepharitis and/or uveitis . Seasonal allergic conjunctivitis acceptable ( avoid enrollment subject may experience seasonal flareup study period ) . Mild blepharitis/blepharoconjunctivitis , typically associate prostaglandin usage , acceptable . 10 . History ocular trauma ocular infection within 3 month Visit 1 . 11 . History herpes simplex keratitis . 12 . Current proliferative diabetic retinopathy agerelated macular degeneration , unless deem clinically significant Investigator . 13 . Severe dry eye ( eg , clinically relevant superficial punctate keratitis , epithelial erosion cornea , and/or use dry eye medication [ include artificial tear ] frequency exceed 8 application per day ) . 14 . Contact lens wear within one week prior Visit 1 study period ( contact lens wear untreated fellow eye allow ) . 15 . Angle closure occludable angle ( Shaffer gonioscopic grade &lt; 3 ) . 16 . Cataract compromise visualization fundus . 17 . Cuptodisc ( C/D ) ratio &gt; 0.8 . 18 . Any secondary glaucoma OH ( eg , congenital glaucoma , closedangle glaucoma , uveitic glaucoma , pseudoexfoliation syndrome ) . 19 . Pregnancy lactation . 20 . Uncontrolled asthma ( define asthma respond maximum guideline direct therapy ) . 21 . Allergy prostaglandin analogue carbonic anhydrase inhibitor . 22 . Allergy benzalkonium chloride . 23 . History moderate severe renal hepatic impairment . 24 . Participation study investigational product within 30 day prior Visit 1 time study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>POAG</keyword>
	<keyword>OHT</keyword>
	<keyword>OHTN</keyword>
	<keyword>IOP</keyword>
</DOC>